Ngā hua rapu - Ashwin N. Ananthakrishnan

Whakamahine hua
  1. 1
    Environmental Triggers for Inflammatory Bowel Disease

    Environmental Triggers for Inflammatory Bowel Disease mā Ashwin N. Ananthakrishnan

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis

    Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis mā Ashwin N. Ananthakrishnan

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Environmental Risk Factors for Inflammatory Bowel Diseases: A Review

    Environmental Risk Factors for Inflammatory Bowel Diseases: A Review mā Ashwin N. Ananthakrishnan

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Environmental Hygiene and Risk of Inflammatory Bowel Diseases

    Environmental Hygiene and Risk of Inflammatory Bowel Diseases mā Aurada Cholapranee, Ashwin N. Ananthakrishnan

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Economic burden and cost-effectiveness of therapies for <i>Clostridiodes difficile</i> infection: a narrative review

    Economic burden and cost-effectiveness of therapies for <i>Clostridiodes difficile</i> infection: a narrative review mā Akshita Gupta, Ashwin N. Ananthakrishnan

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Review article: vitamin D and inflammatory bowel diseases

    Review article: vitamin D and inflammatory bowel diseases mā V. Pratap Mouli, Ashwin N. Ananthakrishnan

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis

    Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis mā Nienke Z. Borren, Ashwin N. Ananthakrishnan

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Epidemiology of Primary and Secondary Liver Cancers

    Epidemiology of Primary and Secondary Liver Cancers mā Ashwin N. Ananthakrishnan, Veena Gogineni, Kia Saeian

    I whakaputaina 2006
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases

    Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases mā Ashwin N. Ananthakrishnan, Emily L. McGinley

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Pivot to Asia: inflammatory bowel disease burden

    Pivot to Asia: inflammatory bowel disease burden mā Prashant Singh, Ashwin N. Ananthakrishnan, Vineet Ahuja

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Clostridium difficile and inflammatory bowel disease

    Clostridium difficile and inflammatory bowel disease mā Mazen Issa, Ashwin N. Ananthakrishnan, David G. Binion

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Higher Physician Density is Associated with Lower Incidence of Late-stage Colorectal Cancer

    Higher Physician Density is Associated with Lower Incidence of Late-stage Colorectal Cancer mā Ashwin N. Ananthakrishnan, Raymond G. Hoffmann, Kia Saeian

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohnʼs Disease? A Decision Analysis

    Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohnʼs Disease? A Decision Analysis mā Ashwin N. Ananthakrishnan, Joshua R. Korzenik, Chin Hur

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Diet in Treatment of Inflammatory Bowel Diseases

    Diet in Treatment of Inflammatory Bowel Diseases mā Alexa N. Sasson, Ashwin N. Ananthakrishnan, Maitreyi Raman

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Outcomes of Weekend Admissions for Upper Gastrointestinal Hemorrhage: A Nationwide Analysis

    Outcomes of Weekend Admissions for Upper Gastrointestinal Hemorrhage: A Nationwide Analysis mā Ashwin N. Ananthakrishnan, Emily L. McGinley, Kia Saeian

    I whakaputaina 2008
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Management of Inflammatory Bowel Disease in the Elderly Patient

    Management of Inflammatory Bowel Disease in the Elderly Patient mā Ashwin N. Ananthakrishnan, Tamara Donaldson, Karen Lasch, Vijay Yajnik

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review

    AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review mā Ashwin N. Ananthakrishnan, Geoffrey C. Nguyen, Çharles N. Bernstein

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases

    Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases mā David Cheng, Bharati Kochar, Tianxi Cai, Ashwin N. Ananthakrishnan

    I whakaputaina 2022
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Inflammatory bowel disease in the elderly is associated with worse outcomes: A national study of hospitalizations

    Inflammatory bowel disease in the elderly is associated with worse outcomes: A national study of hospitalizations mā Ashwin N. Ananthakrishnan, Emily L. McGinley, David G. Binion

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact

    The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact mā Nienke Z. Borren, Shadi Ghadermarzi, Susan Hutfless, Ashwin N. Ananthakrishnan

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: